1 ϫ 10 TCID 50 group, and 12% of the placebo group ( ). No vaccine-related serious adverse events were 6 1 ϫ 10 P ! .01 reported. The cumulative vaccine infectivity (isolation of bPIV3 and/or bPIV3 seroconversion) after dose 3 was similar in the 2 vaccine groups (87% in the TCID 50 group and 77% in the TCID 50 group) ( 5 6 1 ϫ 10 1 ϫ 10 P p ). Seroconversion rates after dose 3, assessed by means of hemagglutination inhibition assay, after adjustment .46 for decrease in maternal antibody titers, were 67% in the TCID 50 group, 57% in the TCID 50 group, 5 6 1 ϫ 10 1 ϫ 10 and 12% in the placebo group ( ). Isolation of bPIV3 was common after dose 1, dose 2, or dose 3, but only P ! .01 1 of 51 participants in the vaccine groups had bPIV3 isolated after dose 4.
Conclusions. Multiple doses of bPIV3 vaccine were well tolerated and immunogenic in young infants.
Human parainfluenza virus type 3 (hPIV3) is an important respiratory pathogen in young children and accounts for ∼11% of pediatric hospitalizations for acute respiratory tract illnesses [1] [2] . hPIV3 is second only to respiratory syncytial virus (RSV) as a leading cause of bronchiolitis and pneumonia in young infants [2] [3] [4] . Because of the burden of disease associated with hPIV3 in young infants, developing a safe and effective vaccine is an important public health priority. Bovine parainfluenza virus type 3 (bPIV3) has been in clinical development for use in a live intranasal vaccine to protect against hPIV3 disease. The rationale for this approach is that (1) replication of bPIV3 is attenuated in nonhuman primates, presumably because of host-range restriction; (2) bPIV3 and hPIV3 share neutralization epitopes [5] ; (3) vaccination of primates with bPIV3 induces cross-protective immunity against challenge with hPIV3 [6] [7] ; and (4) intranasally administered viral vaccines may offer the advantage of inducing local mucosal immunity, which may correlate with protection against hPIV3 disease. Furthermore, current advances in genetic engineering techniques have presented the possibility of using a suitably atten- Health (NIH) and used the same vaccine materials that were previously tested in the NIH phase 1 and phase 2 studies [10] [11] [12] ; the vaccine was retested for potency and packaged into nasal sprayers. Each dose was 0.2 mL (0.1 mL/nostril) and was administered by intranasal spray by use of the Becton Dickinson Accuspray that is identical to that used to administer the live attenuated influenza vaccine (FluMist; MedImmune Vaccines) [13] . A total of 4 doses of vaccine or placebo, depending on group assignment, were administered at 2, 4, 6, and 12-15 months of age concurrently with routine pediatric vaccines, following the American Academy of Pediatrics recommendations (i.e., diphtheria, tetanus, acellular pertussis [DTaP], Haemophilus influenzae type b conjugate [Hib] , inactivated or oral polio virus [IPV or OPV], hepatitis B, measles, mumps, rubella, and varicella vaccines) (table 1) . Parents/guardians and study staff were blinded to the administered treatment. Parents/guardians recorded potential adverse events on diary cards for 14 days after each dose of the vaccine and were contacted by telephone 14 and 30 days after each dose of the vaccine, to capture additional adverse events. Five serum specimens were collected from the participants: at baseline immediately before dose 1, at 2 months of age; before and 1 month after dose 3, at 6 months of age; and before and 1 month after dose 4 (booster), at 12-15 months of age. At 3 of the 4 investigative sites, a single nasal wash specimen, for isolation of bPIV3, was collected from each subject 5-7 days after each dose. Virus culture specimens were collected for outpatient illnesses during the safety assessment periods (28 days after each dose), and these specimens were not collected to assess vaccine efficacy.
Virological assays. Undiluted nasal wash specimens were stored frozen at Ϫ70ЊC until analyzed. Isolation of bPIV3 was performed by use of Madin-Darby bovine kidney cells. Viral isolates were identified as bPIV3 (vaccine) or hPIV3 (wild-type) by use of indirect immunofluorescence assay with specific monoclonal antibodies [10] [11] [12] .
Serological assays. Hemagglutination inhibition (HI) antibodies against bPIV3 and hPIV3 antigens were measured by use of 0.5% guinea pig red blood cells and 4 hemagglutina- tion units of hPIV3/Washington/1957 strain or bPIV3/Kansas/ 15626/84 strain viruses. The antibody titer was defined as the reciprocal of the highest serum dilution that completely inhibited hemagglutination, according to the standard procedure [14] . The starting serum dilution was 1:4, and the cutoff level of seropositivity was set at 4 [15, 16] . Titers of hPIV3 HI antibodies found at 2 months of age, considered to be of maternal origin, were used as the baseline to define hPIV3 seroconversion at 6, 7, 12-15, and 13-16 months of age, after adjustment of hPIV3 HI antibody titers for a 51-day biological half-life of maternal hPIV3 HI antibody titers [15, 16] . bPIV3 HI antibodies were also detected at 2 months of age, because of cross-reactivity between maternal hPIV3 antibodies and bPIV3 antigens. Therefore, bPIV3 seroconversion was cal- 1 ϫ 10 1 ϫ 10 and 66 in the placebo group-were enrolled. The 3 treatment groups were similar with respect to mean age at dose 1 of the vaccine (9.1, 9.2, and 9.4 weeks, respectively), sex (56%, 42%, and 52% male, respectively), and race/ethnicity (48%, 39%, and 44% Hispanic, respectively; 27%, 32%, and 36% white, respectively).
Safety. Incidence rates of solicited adverse events after each dose of the vaccine are shown in table 2. After dose 1, the most frequently reported solicited adverse events in all 3 groups were runny nose/nasal congestion, irritability, and cough. In general, these events occurred at comparable rates in all groups after all 4 doses except after dose 2, when a significantly higher incidence of fever with temperature у38.1ЊC was found in the vaccine groups compared with the placebo group ( , for P ! .01 each vaccine group compared with the placebo group) (table 2). The elevated temperatures occurred primarily on day 0 or day 1 after dose 2. There were no significant differences between the treatment groups in incidence of fever at higher temperature thresholds (у39.0ЊC) after dose 2 (table 2) . Interestingly, the placebo group had a significantly higher incidence of fever р14 days after dose 3 than the TCID 50 group (41% vs. 18%) 5 1 ϫ 10 ( , by Fisher's exact test), and the placebo group had a P p .012 significantly higher incidence of fever р14 days after dose 4 than both vaccine groups (55% in the placebo group vs. 30% in the TCID 50 group and 28% in the TCID 50 group) 1 ϫ 10 group, but these differences were not statistically significant (P p .097 and , respectively, compared with the placebo P p .057 group;
, for 3 groups overall, by Fisher's exact test) (table P p .084 2). The cough episodes were evenly distributed over the 14 days. Rates of cough were comparable in the vaccine groups and the placebo group after dose 1, dose 3, and dose 4.
It is possible that high maternal bPIV3 HI antibody titers protected 2-month-old infants against fever with temperature у38.1ЊC and/or cough after dose 1 and that, by 4 months of age, the titers decreased sufficiently for the rates of these adverse events to increase after dose 2. To evaluate this possibility, we categorized bPIV3 HI antibody titers at 2 months of age into 4 groups (!4, 4, 8, and у16). No correlation between bPIV3 HI antibody titers at 2 months of age and incidence of fever with temperature у38.1ЊC and/or cough after dose 1 or dose 2 was observed in either vaccine group (table 3) , which supports the hypothesis that the higher incidence of fever or cough after dose 2 was not related to the vaccine.
Eight serious adverse events, all of which resulted in hospitalizations, were reported, and 0 were classified as being vaccine-related. These included 4 events in 4 children in the 1 ϫ 10 5 TCID 50 group (parainfluenza type 1 culture-positive croup 8 days after dose 1, Streptococcus pneumoniae bacterial meningitis 30 days after dose 1, otitis media 12 days after dose 2, and elective surgery for correction of syndactyly 20 days after dose 4), 2 events in 2 children in the TCID 50 group 6 1 ϫ 10 (retropharyngeal abscess 11 days after dose 2 and acute otitis media and rotavirus culture-positive gastroenteritis in 1 child 29 days after dose 2), and 2 events in 1 child in the placebo group (bronchiolitis due to RSV at 38 days after dose 1 and an abdominal mass subsequently diagnosed as neuroblastoma presenting at 27 days after dose 2).
Infectivity. The infectivity of the bPIV3 vaccine was assessed by measurement of the proportion of study participants who either had bPIV3 isolated in nasal wash specimens or had a у4-fold increase in bPIV3 HI antibody titers (table 4) . This analysis was restricted to participants at the 3 sites at which isolation of bPIV3 was assessed. After dose 1, at 2 months of age, 38% of the TCID 50 group and 57% of the 1 ϫ 10 6 5 1 ϫ 10 TCID 50 group had bPIV3 isolated ( , by Fisher's exact P p .20 test). After dose 2, at 4 months of age, 37% of the 5 1 ϫ 10 TCID 50 group and 34% of the TCID 50 group had bPIV3 6 1 ϫ 10 isolated. After dose 3, a similar proportion of participants in each vaccine group (25%) had bPIV3 isolated. After dose 4, only 1 participant in the TCID 50 group had bPIV3 6 1 ϫ 10 isolated. After dose 3, 0 participants in the placebo group had bPIV3 isolated, and 1 participant had hPIV3 isolated at day 6. The cumulative proportion of those in the vaccine groups who had bPIV3 isolated after dose 1, dose 2, or dose 3 was the same (79%). After dose 3, bPIV3 seroconversion rates in the vaccine groups were similar (67% in the TCID 50 group and 5 1 ϫ 10 57% in the TCID 50 group) ( , by Fisher's exact 6 1 ϫ 10 P p .40 test). When rates of isolation of bPIV3 or of seroconversion were combined, after dose 3, the cumulative infectivity rate was 87% in the TCID 50 group and 77% in the 5 6 1 ϫ 10 1 ϫ 10 TCID 50 group ( , by Fisher's exact test). After dose 4, P p .46 only 13% of participants in the vaccine groups developed increases in bPIV3 HI antibody titers.
To evaluate the correlation between passively acquired maternal bPIV3 HI antibodies and isolation of bPIV3 after dose 1 or dose 2, we categorized bPIV3 HI antibody titers at 2 months of age into 4 groups (!4, 4, 8, and у16). No correlation between bPIV3 HI antibody titers at 2 months of age and isolation of bPIV3 after dose 1 or dose 2 was observed in either vaccine group (table 3) . The correlation between preexisting bPIV3 HI antibody titers and development of bPIV3 seroconversion after dose 1 or dose 2 cannot be evaluated, because serum specimens were not collected between dose 1 and dose 2. However, we were able to assess the impact of bPIV3 HI antibody titers on bPIV3 seroconversion after dose 3. Participants in the vaccine groups who had lower preexisting bPIV3 HI antibody titers had significantly higher bPIV3 seroconversion rates than participants in the vaccine groups who had higher preexisting HI bPIV3 antibody titers ( , for the P p .002 TCID 50 group;
, for the TCID 50 group, 5 6 1 ϫ 10 P p .013 1 ϫ 10 by Mantel-Haenszel x 2 test for trend) (table 5) . Immunogenicity. bPIV3 and hPIV3 seroconversion rates are shown in table 6. At all 4 time points, bPIV3 seroconversion rates were significantly higher than hPIV3 seroconversion rates in the vaccine groups, indicating that an antibody response to the bPIV3 vaccine was more likely to be detected by the bPIV3 HI assay than by the hPIV3 HI assay. bPIV3 seroconversion rates increased steadily from 45% before dose 3, at 6 months of age, to 86% after dose 4, at 13-16 months of age, in the TCID 50 group, and from 48% to 100%, respectively, in 5 1 ϫ 10 the TCID 50 group; these rates in the vaccine groups 6 1 ϫ 10 were significantly higher than those in the placebo group (9% before dose 3, at 6 months of age, and 50% after dose 4, at 13-16 months of age) ( , by Fisher's exact test). No vac-P ! .05 cine was given between 7 months of age and 12-15 months of age, but hPIV3 seroconversion rates during the interval increased from 16% to 47% in the placebo group, from 25% to 61% in the TCID 50 group, and from 21% to 46% in 5 1 ϫ 10 the TCID 50 group, indicating that exposure to hPIV3 6 1 ϫ 10 was likely during the interval (table 6) .
DISCUSSION
The present study showed that the bPIV3 vaccine was well tolerated and immunogenic in young infants. In a previous phase 1 study of 19 infants 2-6 months of age, the incidence of fever was not significantly higher in the TCID 50 group 5 1 ϫ 10 after dose 1, compared with that in the placebo group [11] . Although our data after dose 1 are consistent with those in the previous study [11] , a higher incidence of low-grade fever after dose 2 in the vaccine groups was observed in the present study. This higher incidence of low-grade fever may be related to the combined effects of concurrent vaccination with multiple other vaccines (e.g., DTaP, Hib, IPV, or OPV) or may have occurred by chance. Similarly, the higher incidence of fever in the placebo group after dose 3 and dose 4 may be due to chance alone. Larger sample sizes will be required in future studies, to clarify any cause-effect relationship.
After dose 3, 82% (37/45) of those in the vaccine groups were infected with bPIV3, as measured by rates of isolation of bPIV3 or bPIV3 seroconversion, whereas, after dose 4, only low proportions of those in the vaccine groups had increased bPIV3 HI antibody titers (12/ 1 ϫ 10 1 ϫ 10 groups). These data support the hypothesis that 3 primary doses likely provide sufficient immunity against hPIV3. Although data on seroconversion was combined with data on isolation of bPIV3 for the purpose of detecting vaccine infectivity in the present study, these rates may still underestimate the vaccine's infectivity, because viral cultures were obtained only once after each dose. The lower rates of isolation of bPIV3 after dose 1 in the present study (38%-57% in the 2 vaccinated groups) is in contrast to those in a previous study of this vaccine, in which 11 of 12 vaccinees (92%) (2-6 months of age; mean age, 4.3 months) had bPIV3 isolated after dose 1 [11] . This difference may be explained by less frequent collection of nasal wash specimens (only once in the week after vaccination in the present study, compared with 4 specimens obtained р11 days after each dose of vaccine in the previous study). Previous studies and the present study have shown bPIV3 to be safe and immunogenic in young infants [10] [11] [12] . Recent in vitro and animal studies have confirmed the potential of bPIV3 vaccine to serve as a vector to express antigens of hPIV3 and RSV [8, 9] . Future development of the bPIV3 vaccine as a vector for hPIV3, RSV, and other respiratory virus antigens in humans is warranted.
